NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor Conferences.
Details of the company’s participation are as follows:
|Jefferies 2023 Healthcare Conference
Format: Corporate Presentation
Date and Time: Friday, June 9th, 9:00 a.m. ET
Location: New York, NY
H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Format: Corporate Presentation (“on-demand”)
Date and Time: Monday, June 26th
A webcast will be available on atai’s website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. An archived replay of the webcast will be available for up to 30 days.
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.
atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
Chief Financial Officer